Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

• ISPOR •
• 18 May, 2026 •
• •

Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures: Results of a Real-World Survey in the United States

Andrew Sulich, Menaka Bhor, James Hawthorne, Emily Goddard, Molly Edwards, Alastair Hinds, Ted Mikuls

Available materials

• CCR East •
• 1 May, 2026 •
• •

Comparison of Diagnostic Journey and Utilization of Clinical Care Resources in Uncontrolled vs. Controlled Gout in the United States

Jigar Shah, Menaka Bhor, James Hawthorne, Nathan Meyer, Emily Goddard, Molly Edwards, Alastair Hinds, John A. Albert

Available materials

• ECN Workshop •
• 12 March, 2026 •
• •

The Impact of Elevated Serum Urate Levels and Tophi on HRQOL and Daily Functioning in Patients with Uncontrolled Gout

Angelo Gaffo, Bhavisha Desai, Abiola Oladapo, Nana Kragh, Lauren A. Do, Madeline O'Grady, Naomi Schlesinger

• ASN •
• 6 November, 2025 •
• •

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Minesh Rajpal, Vibeke Strand, Rehan Azeem, Ben Peace, Bhavisha Desai, Richard J. Johnson

Available materials